RxDoctor Payments Data

Aurelio Torres Consuegra, MD

Internal Medicine · Pembroke Pines, FLNPI 1376720458

Payments from drug & device makers

$1,776,117in general payments, 2019–2025

Across 970 payments — averaging $1831.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$348K
  • GSK$313K
  • Akebia Therapeutics Inc$312K
  • AstraZeneca$195K
  • Chiesi USA, Inc.$162K
  • Sanofi US Services Inc.$150K
  • plus $296K from 37 others

What the payments were for

  • Food & beverage$6,16799%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,776,117 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$103,339
Medicare patients
125
Services billed
1,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$98,203
EliquisApixaban78$96,122
OzempicSemaglutide71$78,099
JanuviaSitagliptin Phosphate45$67,668
MounjaroTirzepatide46$49,593
TradjentaLinagliptin33$49,061
FarxigaDapagliflozin Propanediol31$39,506
EntrestoSacubitril/Valsartan18$36,603
RybelsusSemaglutide12$34,590
XareltoRivaroxaban25$22,654
ProliaDenosumab12$20,764
LinzessLinaclotide17$20,620
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$14,749
Spiriva HandihalerTiotropium Bromide13$12,945
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$11,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$393$147,264100 claims
Novo NordiskOzempic, Rybelsus$508$112,68983 claims
PfizerEliquis$128,293$96,12278 claims
MerckJanuvia$86$67,66845 claims
AstraZenecaFarxiga, Symbicort$195,047$50,02960 claims
Lilly USA, LLCMounjaro$595$49,59346 claims
NovartisEntresto$347,924$36,60318 claims
AbbVieLinzess, Synthroid$804$25,81768 claims
Johnson & JohnsonXarelto$149$22,65425 claims
AmgenProlia$297$20,76412 claims
GSKTrelegy Ellipta$312,849$10,39812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →